{"title":"Forma Therapeutics and Boehringer Ingelheim Partner to Target Oncology-Relevant Protein-Protein Interactions","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I2.1677","DOIUrl":null,"url":null,"abstract":"Forma Therapeutics has landed a 4-year cancer drug discovery deal with Boehringer Ingelheim that is potentially worth up to US$815 M to discover small molecule therapeutics against oncology-relevant protein-protein interactions. With this deal, Boehringer Ingelheim will join Forma’s list of big pharma partners, which includes Roche, Eisai and Novartis.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"11 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I2.1677","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Forma Therapeutics has landed a 4-year cancer drug discovery deal with Boehringer Ingelheim that is potentially worth up to US$815 M to discover small molecule therapeutics against oncology-relevant protein-protein interactions. With this deal, Boehringer Ingelheim will join Forma’s list of big pharma partners, which includes Roche, Eisai and Novartis.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
